# Odyssey Therapeutics, Inc. (ODTX)

> Source: Nexqual · https://nexqual.com/ODTX · data as of 2026-10-28 20:00 UTC · cite as "Nexqual, Odyssey Therapeutics, Inc. (ODTX), nexqual.com/ODTX" · informational, not investment advice.

**Price:** USD 19.54 (+0.21% on the day) · last close of Oct 28, 2026; US market pre market, not a live price. Prev close 19.5 · day 19.19–20.07 · 52w 15.1–29.05 · market cap $939M · NCM

## Key facts
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $32K; 1 not under a Rule 10b5-1 plan ($32K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 4 Form 4 filings, $30.1M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 35.33 (range 27–44).
- Total return with dividends: 1Y +19.0% vs S&P 500 +13.6%; 5Y +19.0% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD -0.93, revenue estimate $0K.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 326.4x · P/B 2.2x · FCF yield -15.94% · Earnings yield -18.18%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Sr One Capital Management, Llc |  | 1,780 | $32K | 0% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
4 purchases, $30.1M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-11 | Sr One Capital Management, Llc |  | 555,555 | $10.0M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Dimension Capital Ii, L.P. | Director | 1,111,111 | $20.0M | 18 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Leiden Jeffrey M | Director | 5,000 | $100K | 20 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Haas Jason | Chief Financial Officer | 1,000 | $20K | 20 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 35.33 (low 27, high 44).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiated | Buy | $27 |
| 2026-10-09 | Raymond James | Initiated | Outperform | $42 |
| 2026-08-27 | HC Wainwright & Co. | Initiated | Buy | $44 |
| 2026-08-07 | JP Morgan | Target raised | Overweight | $26 → $29 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-05-08) | 5Y (from 2026-05-04) |
|---|---|---|
| Total return | +19.0% | +19.0% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 71.1% | 69.3% |
| Max drawdown | -42.3% (Sep 2026→Oct 2026) | -40.3% (Aug 2026→Oct 2026) |

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 95.97 +0.17% · LGND (Ligand Pharmaceuticals Incorpor) USD 318.78 +2.26% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.81 +1.58% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.9 +2.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.51 +0.92% · ABVX (Abivax SA) USD 89.84 +3.26%

## More
Full page: https://nexqual.com/ODTX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-04)

- "Additional details on both studies are expected to be shared in the second half of 2026."
- "Second Quarter 2026 Financial Results As of June 30, 2026, Odyssey had cash, cash equivalents and marketable securities of $433.1 million, which are expected to fund Odyssey's operations into the second half of 2028."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.93 | $-0.89 | −$0.04 | $0 | 3 |
| Next quarter (ends 2026-12-31) | $-1.01 | $-0.98 | −$0.03 | $0 | 3 |
| Current fiscal year (ends 2026-12-31) | $-4.11 | $-4.22 | +$0.11 | $0 | 2 |
| Next fiscal year (ends 2027-12-31) | $-4.36 | $-3.88 | −$0.48 | $0 | 3 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.27 | −$0.85 | Miss −49.4% | — |
| — | Quarter ended Mar 31, 2026 | −$6.75 | −$1.28 | Miss −427.3% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-10-20 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/0001193125-26-425684-index.htm |
| 2026-09-09 | 8-K | Regulation FD disclosure | https://www.sec.gov/Archives/edgar/data/1882782/000119312526385477/0001193125-26-385477-index.htm |
| 2026-08-06 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1882782/000119312526335822/0001193125-26-335822-index.htm |
| 2026-08-04 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/0001193125-26-331512-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.